Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-genera

Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during the undef

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its mark

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the p

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT

Citizens analyst Reni J. Benjamin reiterates Zymeworks (NASDAQ:ZYME) with a Market Outperform and

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and rai

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F

Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, accor

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow amprelo

B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:ZYME) with a Buy and rais

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises t

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus E

August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and rai

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biot

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises t

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cas

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

The Merger Agreement contains certain customary termination rights for the Company and Parent. Subje

Drugmaker ​Zymeworks ‌said ​on ​Monday ⁠it ​will ​buy ​Theravance ​Biopharma in ‌a $929 ⁠million ​de

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarini

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “C

Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cry

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients rega

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients rega

HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and ma

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biote

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biote

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.59) per share. This is a 96.67 percent decr

HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and ma

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

ZW191 is an ADC engineered to target FRα, a protein expressed in several tumor types, including appr

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare a

Evercore ISI Group analyst Jonathan Miller maintains Zymeworks (NASDAQ:ZYME) with a Outperform an

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and rai